Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients
Status:
Completed
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This is a Phase II, dose-escalation clinical trial conducted in mechanically ventilated
patients receiving sedation no longer than 24 hours. The efficacy, safety, and
pharmacokinetics of remimazolam besylate were evaluated using a randomized, single-blind
design.